About: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1994

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1994 (uk) im Juni 1994 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1994 (ast) scientific article published on 01 June 1994 (en) գիտական հոդված հրատարակված 1994 թվականի հունիսի 1-ին (hy)
publication date	wds:Q71993429-90E5869D-52D0-4890-91A5-21C54F1CDBC2
publication date	1994-06-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q71993429-12DC467E-449E-4C67-80C7-002E271C5DDB wds:Q71993429-55B2BABC-8A8A-4EE9-AEA8-63A06F7686C9 wds:Q71993429-849C2D50-3C51-462D-B81D-97FEBE802E75 wds:Q71993429-AE634560-003E-4D02-BDAE-A3BF209F4B72 wds:Q71993429-D05F065A-66DD-4A8B-B2AE-ECCEAD3169F2 wds:Q71993429-F30B9ED0-2B89-4CDB-AFC3-67CF990B1DE2 wds:Q71993429-F63743A1-60CB-4945-A47C-E701A21845D7 wds:Q71993429-FCEF601E-A242-45AE-B703-2907857AF055
author name string	G Duncker M Heller J Kekow W L Gross E Reinhold-Keller W H Schmitt A Schnabel A Beigel
rdfs:label	Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (en) Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (nl)
skos:prefLabel	Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (en) Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (nl)
name	Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (en) Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (nl)
title	wds:Q71993429-4657776B-CE42-41E1-92A4-E27494AA5B06
title	Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis (en)
page(s)	wds:Q71993429-848DA30C-5E2D-4F57-8D25-767CFA193599
page(s)	919-924
instance of	wds:Q71993429-C64CB72E-B744-43B6-B7A5-2BD746AE2587
instance of	scholarly article
PubMed ID	wds:Q71993429-3A8E9EFE-BA0C-402E-9E10-1F04D0ED5D51
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8003065
PubMed ID	8003065
published in	wds:Q71993429-BA5C6846-D314-4947-B2DB-799C42A04FEE
published in	Arthritis and Rheumatism
issue	wds:Q71993429-528E2D82-7F04-461B-812F-069978EEA77D
volume	wds:Q71993429-C72A5810-A8F0-40B5-99DA-DDEF1373A116
issue	6
volume	37
DOI	wds:Q71993429-C86AF19B-87A1-431B-A895-CA23A141009D
DOI	http://dx.doi.org/10.1002/ART.1780370622
DOI	10.1002/ART.1780370622
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71993429
is cites work of	Primary systemic vasculitis Proinflammatory genotype of interleukin-1 and interleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis Cyclophosphamide for ocular inflammatory diseases Increased expression of CTLA-4 (CD152) by T and B lymphocytes in Wegener's granulomatosis Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078) Pharmacological therapy for Wegener's granulomatosis. Disease assessment and management of the vasculitides Systemic necrotizing vasculitis Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies High plasma levels of the soluble form of CD30 activation molecule reflect disease activity in patients with Wegener's granulomatosis Optimisation of cyclophosphamide therapy in systemic vasculitis Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis Nonresolving or slowly resolving pneumonia Wegener's granulomatosis: current and upcoming therapies Bronchoalveolar lavage cell profiles in Wegener's granulomatosis Rare diseases.3: Wegener's granulomatosis Assessment of disease activity in systemic vasculitis Head and neck manifestations of Wegener's granulomatosis Pulmonary vasculitis: classification, clinical features, and management Rare diseases bullet 11: Churg-Strauss syndrome Relapsing Wegener's granulomatosis: successful treatment with cyclosporin-A Clinical and prognostic value of antineutrophil cytoplasmic antibodies in Wegener's granulomatosis and microscopic polyangiitis: comment on the article by Russell et al How to Define Pathogenicity, Health, and Disease? Aberrant cytokine pattern of the nasal mucosa in granulomatosis with polyangiitis Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis Vasculitides with predominantly renal involvement: influence of age on the mode of presentation. Wegener granulomatosis causing sellar mass, hydrocephalus, and global pituitary failure Strategy for Disease Diagnosis, Progression Prediction, Risk Group Stratification and Treatment-Case of COVID-19 Clinical management and treatment of vasculitis [ANCA-associated vasculitides. Classifying the disease and its activity according to EULAR/EUVAS recommendations] The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature Monthly cyclophosphamide pulses in the treatment of crescentic glomerulonephritis Combination therapy in autoimmune disease: vasculitis Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab.
is cites work of	wds:Q33517496-0814A043-324C-4702-9E46-0704E328344D wds:Q34580419-2C70F706-787D-4A85-BA87-902E1ED08015 wds:Q40895072-819E1F9E-F5DD-4839-82B5-21EFC0EE40DA wds:Q41519660-E2AD8AA5-777B-4608-9CFC-287F9411827E wds:Q59715499-2513C6C2-928D-482C-AFEA-D9016E1DFB91 wds:Q36633133-03E0A925-94A3-4C21-BA43-C7E579974E75 wds:Q34186480-282A5709-EB17-4CA9-96D1-F3BF3DE9E352 wds:Q36197950-37F98F18-F8A7-4203-8078-F6725443877E wds:Q44423468-0C639CCD-0079-4F15-9767-558743FEEC35 wds:Q77567446-E5CF58A9-5D67-4B41-9CFD-4A59AB9B02C3 wds:Q96954777-F9E4DD24-0615-4DD9-9A9E-96978B3BE981 wds:Q34395174-BFB9CE83-B37D-4E0D-A4DF-1738D318F7D4 wds:Q35054063-2DA178A5-C009-4A35-A6CF-E1E10841C689

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software